Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vehicle gel (Xequel Bio, Inc.)
- Development stage
- Unknown
- Lead developer
- Xequel Bio
- Administration
- Topical
01
Overview
The vehicle gel is a topical placebo control developed by Xequel Bio, Inc. for use in clinical trials, specifically for the treatment of deep second-degree thermal burns. It serves as the inactive comparator to Granexin gel, which contains the active peptide aCT1 (alpha-Connexin carboxyl-Terminal 1). The vehicle gel is designed to match the physical characteristics of the active treatment without containing any active pharmaceutical ingredient, allowing for within-subject vehicle-controlled studies to evaluate the efficacy and safety of the active drug in promoting wound healing and reducing inflammation.
- Other names
- vehicle gel
Beyond the preview
Go deeper on vehicle gel (Xequel Bio, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vehicle gel (Xequel Bio, Inc.).